HER2DX®️, The First Genomic Tool For Patients With HER2+ Breast Cancer

Time: 12:00 pm
day: Day One

Details:

  • HER2DX® development, validation and clinical utility
  • HER2DX® IGG/immune signature as a key component of the test
  • Delving into future directions

Speakers: